Pre-made Cinpanemab benchmark antibody ( Whole mAb, anti-SNCA therapeutic antibody, Anti-NACP/PARK1/PARK4/PD1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cinpanemab (BIIB 054), a monoclonal antibody against pathologic alpha-synuclein aggregates, is being developed by Biogen, for the treatment of Parkinson’s disease.
| Products Name (INN Index) | Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody |
|---|---|
| INN Name | Cinpanemab |
| Target | SNCA |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 6ct7:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Neurimmune Therapeutics,Biogen |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Parkinson's disease |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SNCA |
| Package |
